C‐type natriuretic peptide plasma levels increase in patients with chronic heart failure as a function of clinical severity

Ry, Silvia Del; Passino, Claudio; Maltinti, Maristella; Emdin, Michele; Giannessi, Daniela

doi:10.1016/j.ejheart.2004.12.009

Cited by 87 publications

(31 citation statements)

References 15 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In symptomatic HF patients, plasma concentrations of both CNP and NT-proCNP are significantly elevated compared to controls and are associated with HF disease severity expressed by NYHA functional class and EF [134]. Interestingly, CNP levels are also increased in patients with asymptomatic LV dysfunction [135].…”

Section: Undefined Mechanismmentioning

confidence: 99%

Novel Renal Biomarkers to Assess Cardiorenal Syndrome

Brisco

Testani

2014

Curr Heart Fail Rep

View full text Add to dashboard Cite

Renal dysfunction (RD) in heart failure portends adverse outcomes and often limits aggressive medical and decongestive therapies. Despite the high prevalence in this population, not all forms of RD are prognostically or mechanistically equivalent: RD can result from irreversible nephron loss secondary to diabetic or hypertensive kidney disease or it can develop secondary to the HF itself, i.e. the cardiorenal syndrome. Furthermore, filtration is only one aspect of renal performance such that significant renal impairment secondary to cardiorenal syndrome can exist despite a normal glomerular filtration rate. Renal biomarkers have the potential to inform some of the intricacies involved in accurately assessing cardiorenal interactions. This article discusses novel biomarkers for cardiorenal syndrome and their utility in prognosis, diagnosis, and targeted treatment of heart failure-induced RD.

show abstract

Section: Undefined Mechanismmentioning

confidence: 99%

Novel Renal Biomarkers to Assess Cardiorenal Syndrome

Brisco

Testani

2014

Curr Heart Fail Rep

View full text Add to dashboard Cite

show abstract

“…Initial studies of patients with CHF demonstrated that the plasma CNP concentration was similar to that in control subjects [4,5]. More recently, Del Ry et al [18] found that CNP levels were increased in patients with CHF as a function of clinical severity.…”

Section: Discussionmentioning

confidence: 95%

C-type natriuretic peptide production by the human kidney is blunted in chronic heart failure

Kalra¹,

Clague

Coats³

et al. 2009

Clinical Science

View full text Add to dashboard Cite

CNP (C-type natriuretic peptide) is a vasodilatory peptide produced by vascular endothelium and the human heart with a short half-life. CNP has been identified within the human kidney; however, few results are available on whether the human kidney is a systemic source of CNP. The aim of the present study was to establish whether CNP is secreted by the human kidney and if synthesis is blunted in CHF (chronic heart failure). A total of 20 male subjects (age, 57+/-2 years; mean+/-S.E.M.) undergoing CHF assessment (n=13) or investigation of paroxysmal supraventricular arrhythmia (normal left ventricular function in sinus rhythm during procedure) (n=7) were recruited. Renal CNP production was determined from concomitant plasma concentrations in the aorta and renal vein. When considering all subjects, a significant step-up in plasma CNP was found from the aorta to renal vein (3.0+/-0.3 compared with 8.3+/-2.4 pg/ml respectively; P=0.0045). The mean increase in CNP was 5.3+/-2.4 pg/ml (range, -0.9 to +45.3 pg/ml). In patients with CHF, the aortic concentration was 3.3+/-0.4 pg/ml compared with a renal vein concentration of 4.3+/-0.6 pg/ml (P=0.11). In those with normal left ventricular function, the respective values were 2.5+/-0.5 and 15.7+/-6.0 pg/ml (P=0.01). In conclusion, CNP is synthesized and secreted into the circulation by the normal human kidney, where it may have paracrine actions. Net renal secretion of CNP appears to be blunted in patients with CHF.

show abstract

“…One millilitre of plasma was eluted with a 1-ml volume of 60% acetonitrile mixed in a 1% trifluoracetic acid (TFA) solution for the solidphase extraction step, as previously described by del Ray et al 7…”

Section: Methodsmentioning

confidence: 99%

“…After the remaining product was dissolved in 300–500 μl of assay buffer, 100 μl of the resulting mixture was used to perform the immunometric assay 7. The average CNP recovery was calculated to be 74.8%.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic value of plasma C-type natriuretic peptide levels in determination of the duration of mesenteric ischaemia : cardiovascular topic

Demirtaş¹,

Karahan²,

Yazici³

et al. 2014

CVJA

View full text Add to dashboard Cite

SummaryObjectiveMesenteric arteries release C-type natriuretic peptide (CNP), which hyperpolarises vascular smooth muscle. We measured the levels of this peptide after inducing mesenteric ischaemia over a series of time intervals, so as to determine its predictive value in demonstrating the severity of ischaemia in a rat model.MethodsA total of 32 rats were allocated to four groups containing eight rats each. Basal CNP reference levels were measured in the control group, which was not exposed to any intervention. In groups I, II and III, mesenteric ischaemia was induced over three, six and nine hours, respectively, and plasma CNP levels were measured afterwards. Mesenteric ischaemia was induced by clamping the superior mesenteric artery.ResultsIn comparison with the controls (2.38 ± 0.18 pg/ml), CNP levels were relatively lower in group I (2.54 ± 0.42 pg/ml). However, significant increases in plasma CNP levels were observed over longer periods of ischaemia in group II, at 5.23 ± 0.22 pg/ml, and in group III, at 6.19 ± 0.67 pg/ml (p < 0.05). A significant direct relationship was determined between plasma CNP levels and prolonged intervals of mesenteric ischaemia (R = 0.56, p < 0.001).ConclusionMeasuring plasma CNP levels in patients with acute mesenteric ischaemia may be beneficial in estimating the time period over which the ischaemic injury has occurred.

show abstract

C‐type natriuretic peptide plasma levels increase in patients with chronic heart failure as a function of clinical severity

Cited by 87 publications

References 15 publications

Novel Renal Biomarkers to Assess Cardiorenal Syndrome

Novel Renal Biomarkers to Assess Cardiorenal Syndrome

C-type natriuretic peptide production by the human kidney is blunted in chronic heart failure

Diagnostic value of plasma C-type natriuretic peptide levels in determination of the duration of mesenteric ischaemia : cardiovascular topic

Contact Info

Product

Resources

About